Period:
Draw Mode:
| Volume | 1,624,609 |
|
|||||
| News | - | ||||||
| Day High | 4.08 | Low High |
|||||
| Day Low | 3.99 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MannKind Corporation | MNKD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.25% | 4.05 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.08 | 3.99 | 4.08 | 4.01 | 4.06 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,061 | 1,624,609 | $ 4.03 | $ 6,554,913 | - | 2.91 - 5.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:39:21 | formt | 114 | $ 4.05 | USD |
MannKind (MNKD) Options Flow Summary
MannKind Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.09B | 268.36M | - | 99.77M | -87.4M | -0.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MannKind News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNKD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.45 | 4.64 | 3.99 | 4.19 | 2,410,968 | -0.40 | -8.99% |
| 1 Month | 4.72 | 4.94 | 3.99 | 4.39 | 2,466,447 | -0.67 | -14.19% |
| 3 Months | 3.95 | 5.75 | 3.89 | 4.71 | 2,746,205 | 0.10 | 2.53% |
| 6 Months | 4.04 | 5.75 | 3.70 | 4.40 | 2,951,939 | 0.01 | 0.25% |
| 1 Year | 3.08 | 5.75 | 2.91 | 4.40 | 3,462,529 | 0.97 | 31.49% |
| 3 Years | 1.86 | 6.25 | 1.78 | 4.08 | 3,790,038 | 2.19 | 117.74% |
| 5 Years | 1.95 | 6.25 | 0.80 | 3.27 | 3,294,962 | 2.10 | 107.69% |
MannKind Description
| MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |